(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...
AbbVie (ABBV) has built a solid reputation among passive income-focused investors, backed by an impressive 54-year streak of ...
April 29 (Reuters) - AbbVie on Wednesday reported better-than-expected quarterly revenue and profit, fueled by demand for newer immunology drugs Skyrizi and Rinvoq, as the drugmaker continues to ...
This year, CVS Health plans to employ the classic "out with the old, in with the new" mantra when it comes to AbbVie’s Humira. Come April 1, the branded drug will be replaced by cheaper biosimilars ...
No more waiting: Humira’s judgment day has finally arrived. The first Humira biosimilar, Amgen’s Amjevita, is set to reach the market Tuesday and kick off a tsunami-sized wave of competition. With ...
Ideal for uncertain times. Dividend stocks with long track records of dividend increases tend to have stable underlying ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...
(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results